CyPath® Lung is being developed to detect early-stage lung cancer, a disease that claims nearly 1.4 million lives worldwide and nearly 160,000 Americans each year. A staggering 60% of patients with lung cancer die within one year after diagnosis. Studies show that early detection can increase the survival rate to more than 90% if lung cancer is caught and treatment can begin in the earliest stage.
bioAffinity’s CyPath® Lung analyzes a person’s sputum, or phlegm, to find cancer cells that have sloughed off a lung tumor during collection of the sample. To get a sample, a person blows into a simple, non-invasive assist device that acts to break up mucus and help a person cough up the phlegm. The sputum sample is shipped to the laboratory, prepared for analysis and labeled with CyPath®. Cancer cells in the sample fluoresce brightly as compared to non-cancer cells when viewed microscopically. By comparing the fluorescence, cancer can be identified.
Current screening for lung cancer calls for using low dose computed tomography (LDCT) that finds earlier stage cancer to increase survival, but has a high false-positive rate of more than 96% and can lead to unnecessary invasive procedures.
CyPath® Lung has the ability to dramatically increase overall accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.
Through its subsidiary, OncoSelect Therapeutics, our Company focuses on expanding its broad platform technology to create targeted porphyrin therapeutics to fight cancer. Chemotherapy and other cancer-killing drugs can be attached to the cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue. OncoSelect Therapeutics will be developing a diverse number of targeted therapeutics based on the platform technology to provide novel drugs in the fight against cancer.
bioAffinity Technologies is proud to play a part in the University of Texas Health video highlighting our impressive research collaboration to uncover the mechanisms of cancer. The collaboration with the University of Texas, a leader in innovation, has led to exciting advancements that further the development and commercialization of our life-saving tests and treatments for cancer. In this video, you’ll see physicians, scientists, and bioAffinity Technologies CEO Maria Zannes discuss how medical breakthroughs are being commercialized and made available to those who need them, including more about how we’re moving forward with our CyPath® diagnostic tests and OncoSelect® therapeutics.